XT-150

BIOLOGICAL8 trials

Sponsors

Xalud Therapeutics, Inc.

Conditions

Amyotrophic Lateral Sclerosis (ALS)Back PainFacet Joint PainInflammationNeuropathic PainOsteoarthritis, KneeOsteoarthritis, Spine

Phase 1

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

CompletedNCT03282149

Xalud Therapeutics, Inc.Osteoarthritis, Knee

Start: 2018-03-21End: 2019-06-15Updated: 2019-07-05

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

CompletedNCT03477487

Xalud Therapeutics, Inc.Osteoarthritis, Knee

Start: 2018-06-08End: 2019-09-30Updated: 2019-11-08

Follow on Extension of XT-150-1-0201

CompletedNCT03769662

Xalud Therapeutics, Inc.Osteoarthritis, Knee

Start: 2019-03-20End: 2019-12-30Updated: 2020-01-18

Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain

TerminatedNCT04466410

Xalud Therapeutics, Inc.Neuropathic Pain

Start: 2021-04-14End: 2022-09-27Updated: 2023-01-23

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

WithdrawnNCT04841512

Xalud Therapeutics, Inc.Osteoarthritis, Spine

Start: 2021-10-31End: 2022-03-01Updated: 2022-03-17

Safety Study of XT-150 in Participants With ALS

Not yet recruitingNCT06704347

Xalud Therapeutics, Inc.Amyotrophic Lateral Sclerosis (ALS)

Start: 2027-03-01End: 2028-06-01Target: 8Updated: 2026-07-29

Phase 2

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

CompletedNCT04124042

Xalud Therapeutics, Inc.Osteoarthritis, Knee

Start: 2020-02-14End: 2022-04-26Updated: 2025-03-27

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

CompletedNCT05196919

Xalud Therapeutics, Inc.Back Pain, Facet Joint Pain, Inflammation

Start: 2022-02-24End: 2023-09-20Updated: 2025-01-15